Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer

5 Feb 2025

Abstract excerpt

We here investigate the expression of the mitochondrial carrier homolog 2 (MTCH2) and its potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses reveal that MTCH2 overexpression is associated with critical clinical parameters of prostate cancer. Single-cell sequencing data indicate elevated MTCH2 expression in the prostate cancer epithelium. MTCH2 is also upregulated in locally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Ferroptosis and cancer prognosis
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39910035
DOI: 10.1038/s41419-025-07406-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancerPMID 39910035Read ↗

MTCH2 in Metabolic Diseases, Neurodegenerative Diseases, Cancers, Embryonic Development and ReproductionSemantic proximity Read ↗

Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant gliomaSemantic proximity Read ↗

Inhibition of Mitochondrial Carrier Homolog 2 (MTCH2) Suppresses Tumor Invasion and Enhances Sensitivity to Temozolomide in Malignant GliomaSemantic proximity Read ↗

Mitochondrial Alterations in Prostate Cancer: Roles in Pathobiology and Racial DisparitiesSemantic proximity Read ↗

High mitochondria content is associated with prostate cancer disease progressionSemantic proximity Read ↗

Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.Semantic proximity Read ↗

PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2Semantic proximity Read ↗

CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia-induced invasion, and therapeutic resistanceSemantic proximity Read ↗

MTCH2 promotes the malignant progression of ovarian cancer through the upregulation of AIMP2 expression levels, mitochondrial dysfunction and by mediating energy metabolismSemantic proximity Read ↗

A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate CancerSemantic proximity Read ↗

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Semantic proximity Read ↗

Clusterin: a key player in cancer chemoresistance and its inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.